Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study
Authors' conclusion
Sleep impairment in RA patients can improve with treatment. Actigraphy showed improvements, particularly in patients with high subjective sleep impairment who achieve remission.
Study context
- Population
- Patients with rheumatoid arthritis (RA) treated with upadacitinib (UPA) in real-world practice
- Participants
- 39 patients
- Exposure
- Sleep quality before vs after UPA treatment
- Outcome
- Total PSQI, change from baseline
- Follow-up
- 3 months
Methodological detailssub-study of UPHOLD, international, prospective follow-up, actigraphy, Pittsburgh Sleep Quality Index (PSQI) at baseline and months 3, 6, 12 and 24; actigraphy at baseline and month 3
- Sub-study of UPHOLD
- International
- Prospective follow-up
- Actigraphy
- PSQI at baseline and months 3, 6, 12 and 24; actigraphy at baseline and month 3
Main finding
As reported in the abstract
- Total PSQI significantly improved
- −2.42
- P value
- p < 0.001
- Actigraphy outcomes, whole cohort
- remained unchanged
Observational data: associations, not effects.
Further findings
Baseline actigraphy sleep efficiency by PSQI category
Baseline sleep: impaired subjective sleep quality
- Impaired subjective sleep quality
- 76%
- Total PSQI
- 7.84
Patients with impaired sleep quality at baseline (n=19) · 3 months
- Achieved good sleep quality
- 8
- Actigraphy sleep efficiency
- + 1.5%
- Total wake time
- −7.3 min
- Movement index
- −0.7%
Shift from objectively impaired to good sleep efficiency
- Only observed in patients achieving remission or normative values of pain and fatigue
Original publication
Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study. Arthritis Res Ther. Published 27 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →